

ROSE E. SEKULOVICH, Ph.D.

San Diego, CA 92130
[linkedin.com/in/rosesekulovich](https://www.linkedin.com/in/rosesekulovich)

Cell: (858) 449-1397
[E-mail: rsekulovich@gmail.com](mailto:rsekulovich@gmail.com)

BIOPHARMA RESEARCH AND DEVELOPMENT MANAGEMENT

A senior scientist with a proven track record in managing large lab groups in research and development activities. Demonstrated, strong background in all aspects of phase-appropriate project planning and implementation from pre-IND through licensure, and experience with global project teams. Expertise includes:

- Extensive experience in R&D biologics and therapeutics, including development of bacterial and viral vaccines, gene therapies for oncology, and protein and peptide-based therapeutic products.
- Leadership of Assay Development and Quality Control functions in small, mid-sized and large biopharma companies (including study design, method and equipment qualification and validation, product release, and stability tracking and trending).
- International Project Team experience.
- Preparation of regulatory documents and filings.
- Laboratory planning and implementation of GXP systems.
- Management of commercial release and stability programs.
- Management of contracted laboratory services.

PROFESSIONAL EXPERIENCE

ALTHEA TECHNOLOGIES, INC., San Diego, CA 2010 – present

Director, Analytical Development

Director of analytical methods development for small molecules, peptides and proteins for early phase through commercial products contracted through Althea Technologies, Inc. Responsible for client interactions, technical input, contractual agreements, and marketing interface for analytical programs.

- Technical liaison for client activities, including development, transfer and qualification or validation of product-specific methods, in coordination with the Camarillo, CA laboratories.
- Technical liaison for Althea Sales and Marketing and Program Management groups
- Responsible for contractual agreements for analytical activities.
- Development of new technologies for strategic expansion of Althea's analytical division.

AMYLIN PHARMACEUTICALS, INC., San Diego, CA 2004 – 2009***Director, Bioanalytical Chemistry 2007 – 2009***

Director of bioanalytical method development, validation and assay services in support of all nonclinical and clinical R&D programs for Amylin Pharmaceuticals, Inc. Led a staff of up to 40 employees, including senior level scientists and managers.

- Directed development and implementation of assays in support of early Research programs.
- Directed development and implementation of assays in support of Development programs up to and including phase III clinical trials.
- Directed outsourcing activities and contract lab management and oversight.
- Provided GLP oversight and compliance, Quality Lead Team representation, PAI preparedness.
- Implemented new technologies and assay automation systems.
- Participated in Due Diligence activities for Business Development.
- Wrote Bioanalytical sections of Regulatory submissions.

Director, Protein Analytics 2006 – 2007

Director of activities related to development and validation of analytical methods for proteins and peptides, with an emphasis on recombinant protein technologies.

- Supervised method transfer activities between Amylin and contract service providers and between contract service providers.
- Led all aspects of analytical support for protein drug substance, drug product and related devices, including direction of protein-based analytical activities at Amylin, close coordination of activities with other internal Amylin departments, and interaction with contract laboratories and manufacturing sites.
- Managed analytical development and testing activities at contract laboratories for Amylin R&D programs.
- Provided scientific and technical support to contract service providers for peptide and protein products.
- Wrote analytical sections for CMC regulatory submissions.

Director, Quality Operations 2004 – 2006

Director of laboratory, manufacturing, stability and quality systems functions (total staff ~30), with responsibility for batch disposition of clinical and commercial products.

- Directed quality oversight and batch disposition of commercial and development materials for all Amylin programs.
- Management of external analytical contract labs for Amylin commercial products.
- Supervised data integrity review of all regulatory submissions for Amylin.
- Quality Operations representative for Lilly Alliance.
- Project sub-team representative for Quality group (Leptin due diligence team, Exenatide Once Weekly (EQW) Facilities build-out team, IND Guidance Board).

MEDIGENE, INC., San Diego, CA 2000 – 2003***Director, Project Management 2003***

Global Project Manager for all Herpes Simplex virus oncolytic products for MediGene, Inc. Managed a global development team with oversight for process development, preclinical, clinical, regulatory, CMC and marketing functions.

- Led project teams for development of G207 (phase I trial for glioblastoma multiforme) and NV1020 (phase I/II for colorectal metastases to the liver).
- Led project planning and tracking, organized project meetings, maintained the product development timelines, prepared the project development plans, updates to senior management, timelines, budget, and risk analysis.

Director, Assay Development and Quality Control 2000 – 2003

Built and directed an Assay Development and QC group for MediGene, Inc. (14 staff members, including four scientists). Coordinated and designed facilities and laboratory build outs, and made major equipment purchases. Led assay development activities for Preclinical, Research, Process Development, and Quality Control. In QC, managed assay qualification for process development activities and product release testing, and implemented quality systems in laboratories and documentation (SOPs, task reports, scientific reports). Developed and administered an annual budget of ~ \$4M.

- Led a multi-disciplinary team in development of product-specific assays for characterization of HSV oncolytic products (including, but not limited to cell-based assays, protein assays, immunoassays, real time and quantitative PCR, epifluorescent microscopy, and HPLC).
- Developed a validation plan in anticipation of late-stage development programs.
- Ensured compliance with GLPs and GMPs.
- Managed interactions with CROs on contracted assay development as well as assay transfer activities.
- Collaborated with external scientists on novel assay methods development.
- Wrote regulatory submissions to the FDA.
- Presented at Scientific Advisory Board meetings, and at strategic planning sessions.

CHIRON CORPORATION, Emeryville, CA 1988 – 2000***Associate Director, Analytical Biology 1998 – 2000***

Directed a department of 11 staff, including five scientists. Led the team in development and validation of immunoassays and bioassays to support preclinical and clinical development, pharmacology and toxicology, process development, manufacturing and quality control. Administered an annual budget of ~\$2M.

- Supported licensed products (BetaseronTM, ProleukinTM), and products in different stages of clinical development (including, but not limited to TFPI, IGF-1, Factor VIII, DNA vaccines).
- Worked on global project teams for clinical development of biologic products.

- Led a team of development scientists in compiling the CMC section for the Menjugate™ vaccine BLA; contributed to the successful regulatory filing for Menjugate™ in the United Kingdom.
- Represented the Process Development division on the Internal Biosafety Committee (IBC).

Senior Scientist ***1997 – 1998***

Directed a department of seven, including one scientist. Led assay activities and data transfer for the Menjugate™ phase II clinical trials including assay development and validation (cell-based bactericidal assay and high avidity immunoassays), as well as verification of clinical database.

- Worked on global project exams for clinical development of vaccine products.
- Acted as scientific liaison with California Department of Health Services for clinical serology for Fluvad™ clinical trials (subunit flu antigens adjuvanted with MF59, Chiron's proprietary vaccine adjuvant). Managed database transfer and verification for these trials.
- Worked with the Business Development group on evaluating partnering opportunities for MF59 with veterinary vaccine companies.

Principal Scientist ***1995 – 1997***

Directed a group of eight, including two scientists. The group performed clinical assays (cell-based assays and immunoassays) for the phase II HSV vaccine program. Led development of clinical assays for the CMV vaccine and CMV Ig programs, including collaboration with our business partner.

- Led assay development and validation for the HSV vaccine program. Collaborated with an external lab for our phase III endpoint methodology (Dr. Rhoda Ashley, University of Washington; Western blot).
- Successfully transferred CMV assay methodologies to business partner.
- Managed the Fluvad™ immunoassay program and coordinated assay validation activities at our contract lab (California Department of Health Sciences) for the European dossier.
- Worked on global teams for clinical development of vaccine products.

Scientist ***1992 – 1994***

Managed a group of five research associates and one scientist. Directed clinical assay and data transfer activities for phase I and II HSV vaccine trials for immunoprophylaxis and immunotherapy. Initiated assay development and qualification for phase III HSV studies.

- Collaborated with Dr. Steve Kohl (UCSF) to monitor ADCC responses in our HSV vaccine recipients. Successfully transferred the assay methodology to Chiron.
- Established and directed contract assays (HAI using Chiron subunit antigens) with California Department of Health Services for serology on the Fluvad™ programs.
- Developed a high throughput robotics system for automating ELISAs and data capture for clinical programs.
- Developed standardized methods (with the IT group) for sample receipt, log-in, assay tracking, and data transfer from the assay group to the clinical data management group.
- Established an archival freezer system for storage and retrieval of clinical samples.
- Worked on project teams for clinical development of vaccine products.

Postdoctoral Scientist ***1988 – 1991***

Performed research on HSV vaccine development, including construction of viral vectors and preclinical testing and evaluation in mouse and guinea pig models (contributed to filing of HSV vaccine IND). Worked with the Chiron vaccines adjuvant group to plan and conduct preclinical experiments on novel vaccine candidates.

- Implemented vaccinia vector technology at Chiron vaccines, including scientific methods, establishment of EH&S standards for virus handling, and vaccination programs for staff.
- Trained and managed research associates and student interns in the laboratory.
- Filed a patent on work done to identify a novel vaccine target in HSV-2 (issued in 1991).

EDUCATION

Ph.D., Microbiology and Molecular Genetics – School of Medicine, University of California, Irvine, CA

Thesis: A Genetic and Biochemical Analysis of the role of the Immediate Early Polypeptides ICP0 and ICP27 in the Regulation of Herpes Simplex Virus Type I Gene Expression

B.A., Biology and English/American Literature (with Honors) – Revelle College, University of California, San Diego, CA

PROFESSIONAL TRAINING

- | | |
|--|--|
| <i>Regulatory Affairs Professionals Society</i>
<i>(2003)</i> | <ul style="list-style-type: none"> • IND Creation and Regulatory Roles • IND Life Cycle • Influencing the IND: Special Topics |
| <i>Microsoft Project Training (2000)</i> | <ul style="list-style-type: none"> • Intro to MS Project • Intermediate MS Project • MS Access |
| <i>International Business Communications, “FDA Survival Summit” (2000)</i> | <ul style="list-style-type: none"> • FDA Team Biologics Field Inspections • Investigating OOS Test Results |
| <i>Chiron in-house Workshops and Training (1998-2000)</i> | <ul style="list-style-type: none"> • Annual Compliance Training (min. 4 hours required) • International Conference on Harmonization (ICH): Quality Guidelines • Project Management Workshop |
| <i>Sexual Harassment Prevention Training for Management</i>
<i>Managing Conflict for Management</i> | |

FELLOWSHIPS

University of California Regents Fellowship (1981 – 1983)
National Institutes of Health Training Grant, “Regulation of Gene Expression,” GM07134 (1982 – 1986)
University of California Campus Biotechnology Training Program Fellowship (1986 – 1987)
University of California Regents’ Dissertation Fellowship (1987)

AWARDS

General Dynamics “Outstanding Scholar” Scholarship (1973)
University of California Regents Scholarship (1973 – 1978)
California State Merit Scholarship (1973 – 1977)
San Diego Heart Association Research Scholarship (1975 – 1976)

PROFESSIONAL AFFILIATIONS

American Society of Microbiology
American Association of Pharmaceutical Scientists
UCSD Alumni Association

PATENTS

- R.L. Burke and **R.E. Sekulovich**: Herpes Simplex Virus VP16 Vaccines (1991)

LANGUAGE SKILLS

Verbal ability in Spanish, French and Serbo-Croatian.

PUBLICATIONS

Manuscripts

M.W. Drulak, F.J. Malinoski, S.A. Fuller, S.S. Stewart, S. Hoskin, A.M. Duliege, R. Sekulovich, R. Burke, S. Winston. Vaccination of Seropositive Subjects with CHIRON CMV gB Subunit Vaccine Combined with MF59 Adjuvant for Production of CMV Immune Globulin. *Viral Immunol* 13(1): 49-56 (2000).

S. Kohl, E.D. Charlebois, M. Sigouroudinia, C. Goldbeck, K. Hartog, R.E. Sekulovich, A.G. Langenberg, R.L. Burke. Limited Antibody-Dependent Cellular Cytotoxicity Antibody Response Induced by a Herpes Simplex Virus Type 2 Subunit Vaccine. *Journal Infectious Disease* 181(1): 335-9 (2000).

S.E. Frey, C. Harrison, R.F. Pass, E. Yang, D. Boken, R.E. Sekulovich, S. Percell, A.E. Izu, S. Hirabayashi, R.L. Burke, A.M. Duliege. Effects of Antigen Dose and Immunization Regimens on Antibody Responses to a Cytomegalovirus Glycoprotein B Subunit Vaccine. *Journal Infectious Disease* 180(5): 1700-3 (1999).

R.F. Pass, A.M. Duliege, S. Boppana, R. Sekulovich, S. Percell, W. Britt, R.L. Burke. A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B and a New Adjuvant. *Journal Infectious Disease* 180(4): 970-5 (1999).

L. Corey, A.G. Langenberg, R. Ashley, R.E. Sekulovich, A.E. Izu, J.M. JR. Douglas, H.H. Handsfield, T. Warren, L. Marr, S. Tying, R. DiCarlo, A.A. Adimora, P. Leone, C.L. Dekker, R.L. Burke, W.P. Leong, S.E. Straus. Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection: Two Randomized Controlled Trials. Chiron HSV Vaccine Study Group. *JAMA* 28:282(4): 331-40 (1999).

S.S. Terhune, K.T. Coleman, R. Sekulovich, R.L. Burke, P.G. Spear. Limited Variability of Glycoprotein Gene Sequences and Neutralizing Targets in Herpes Simplex Virus Type 2 Isolates and Stability on Passage in Cell Culture. *Journal Infectious Disease* 178(1): 8-15 (1998).

R.L. Ashley, F.M. Crisostomo, M. Doss, R.E. Sekulovich, R.L. Burke, M. Shaughnessy, L. Corey, N.L. Polissar, A.G. Langenberg. Cervical Antibody Responses to a Herpes Simplex Virus Type 2 Glycoprotein Subunit Vaccine. *Journal Infectious Disease* 178(1): 1-7 (1998).

RL. Ashley, J. Dalessio, R.E. Sekulovich. A Novel Method to Assay Herpes Simplex Virus Neutralizing Antibodies Using BHKICP6LacZ-5 (ELVIS) Cells. *Viral Immunol* 10(4): 213-20 (1997).

S.E. Straus, A. Wald, R.G. Kost, R. McKenzie, A.G. Langenberg, P. Hohman, J. Lekstrom, E. Cox, M. Nakamura, R. Sekulovich, A. Izu, C. Dekker, L. Corey. Immunotherapy of Recurrent Genital Herpes with Recombinant Herpes Simplex Virus Type 2 Glycoproteins D and B: Results of a Placebo-Controlled Vaccine Trial. *Journal Infectious Disease* 176(5): 1129-34 (1997).

A.G. Langenberg, R.L. Burke, S.F. Adair, R. Sekulovich, M. Tigges, C.L. Dekker, L. Corey. A Recombinant Glycoprotein Vaccine for Herpes Simplex Virus Type 2: Safety and Immunogenicity [Corrected] *Annals of Internal Medicine* 15(12): 889-98 (1995).

S.E. Straus, L. Corey, R.L. Burke, B. Savarese, G. Barnum, P.R. Krause, R.G. Kost, J.L. Meier, R. Sekulovich, S.F. Adair, et al. Placebo-Controlled Trial of Vaccination with Recombinant Glycoprotein D of Herpes Simplex Virus Type 2 for Immunotherapy of Genital Herpes. *Lancet* 343(8911): 1460-3 (1994).

M.A. Tigges, D. Koelle, K. Hartog, R.E. Sekulovich, L. Corey, R.L. Burke. Human CD8+ Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones Recognize Diverse Virion Protein Antigens. *Journal of Virology* 66(3): 1622-34 (1992).

I.L. Smith, R.E. Sekulovich, M.A. Hardwicke, R.M. Sandri-Goldin. Mutations in the Activation Region of Herpes Simplex Virus Regulatory Protein ICP27 Can Be Trans Dominant. *Journal of Virology* 65(7):3656-66 (1991).

M.A. Hardwicke, P.J. Vaughan, R.E. Sekulovich, R. O'Conner, R.M. Sandri-Goldin. The Regions Important for the Activator and Repressor Functions of Herpes Simplex Virus Type 1 Alpha Protein ICP27 Map to the C-Terminal Half of the Molecule. *Journal of Virology* 63(11): 4590-602 (1989).

K. Leary, H.H. Yim, L.B. Zhou, R.E. Sekulovich, R.M. Sandri-Goldin. The Influence of the Herpes Simplex Virus-1 DNA Template Environment on the Regulation of Gene Expression. *Virus Genes* 3(1): 57-68 (1989).

R.E. Sekulovich, K. Leary, R.M. Sandri-Goldin. The Herpes Simplex Virus Type 1 Alpha Protein ICP27 Can Act as a trans-Repressor or a trans-Activator in Combination with ICP4 and ICP0. *Journal of Virology* 62(12): 4510-22 (1988).

R.M. Sandri-Goldin, R.E. Sekulovich, K. Leary. The Alpha Protein ICP0 Does Not Appear to Play a Major Role in the Regulation of Herpes Simplex Virus Gene Expression During Infection in Tissue Culture. *Nucleic Acids Res.* 15(3): 905-19 (1987).

Abstracts

Poster: 15th International Herpesvirus Workshop, Georgetown University, Washington, D.C. (1990). "Human Cytotoxic Cell Clones to Herpes Simplex Type 2," M.A. Tigges, R.E. Sekulovich, D. Koelle, L. Corey, and R.L. Burke.

Poster: 16th International Herpesvirus Workshop, Asilomar, California (1991). "Persistence of Antibody to HSV-2 gB in a Guinea Pig Model: Priming with Live Virus Vectors versus Liposome Formulations," R.E. Sekulovich, G.L. Barchfeld, G. Ott, G. Van Nest, and R.L. Burke.

Talk: Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim California (1992). "A Phase I Study of Recombinantly Produced Herpes Simplex Virus (HSV) Glycoproteins gD2 and gB2 Combined with a Novel Adjuvant MF59/MTP-PE," C.L. Dekker, S.F. Adair, R.E. Sekulovich, N. Niland, and R.L. Burke.

Talk: Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim California (1992). "A Highly Immunogenic Recombinant HSV-2 Glycoprotein Vaccine: -gD2 AND gB2 in the Microfluidized Adjuvant MF-59," L. Corey, C. Dekker, S. Adair, R. Sekulovich, and R.L. Burke.

Poster: Eleventh International Symposium on Laboratory Automation and Robotics, Boston, Massachusetts (1993). "Automation of an ELISA for Detection of Antibody to Two Antigens and Data Processing of Vaccine Clinical Trial Samples," J. Patrick McCurley, Eric Hall, Mark Westley, Rick Najarian, and Rose Sekulovich.

Talk: Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida (1994). "Addition of Recombinant HSV-2 gB to a gD2 Vaccine Improves the Kinetics, Magnitude, and Durability of Antibody Responses in Humans," A. Langenberg, R. Sekulovich, J. Douglas, S.E. Straus, G.J. Mertz, R.L. Burke, A. Izu, C. Dekker, and L. Corey.

Talk: Seventh European Congress of Clinical Microbiology and Infectious Disease, Vienna, Austria (1995). "Safety and Immunogenicity of Biocine Adjuvanted Influenza Vaccine in Elderly Subjects," T. Martin, S. De Donato, A. Minutello, G.L. Lecchi, S. Adair, V. Pellegrini, R. Sekulovich, G. Van Nest.

Talk: Society for Pediatric Research, San Diego, California (1995). "Immunogenicity of Recombinant CMV gB Vaccine," Robert F. Pass, Anne-Marie Duliege, Suresh B. Boppana, William J. Britt, Dan M. Granoff, Rose Sekulovich, and Rae Lyn Burke.

Poster: 18th International Herpesvirus Workshop, Pittsburgh, Pennsylvania (1993). "The Increased Immunogenicity of a HSV Glycoprotein Subunit Vaccine Combined with the Novel Adjuvant MF59 as Compared to Alum as Adjuvant," R.L. Burke, R. Sekulovich, M. Tigges, A. Langenberg, S. Adair, C. Dekker, G. Ott, G. Van Nest, S. Straus, and L. Corey.

Talk: Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana (1993). "Safety and Immunogenicity of a Subunit HSV-2 Glycoprotein gB2-gD2 Vaccine in MF59 Adjuvant," A. Langenberg, L. Corey, R.L. Burke, R. Sekulovich, S. Adair, and C. Dekker.

Talk: Fifth International Cytomegalovirus Conference, Stockholm, Sweden (1995). "A Phase I Trial of Biocine CMV gB Vaccine in Seronegative Adults," Robert F. Pass, Ann-Marie Duliege, Suresh B. Boppana, William J. Britt, Dan M. Granoff, Rose Sekulovich, and Rae Lyn Burke.

Talk: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California (1995). "Enhanced Immunogenicity of Chiron Biocine Adjuvant Influenza Vaccine in the Elderly," T. Martin, R. Gasparinin, S. De Donato, A. Ambrozaitis, J. Schwartz, P. Crovari, S. Gravenstein, R. Sekulovich, E. Baylis, G. Van Nest, S. Adair, A. Minutello, A. Podda, C. Dekker.

Talk: Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, California (1995). "Cervical IgG and IgA responses to a Herpes Simplex Virus-2 (HSV-2) Subunit Vaccine. R. -Ashley, L. Corey, A. Langenberg, R.L. Burke, R. Sekulovich, C. Gee, C Dekker, A. Wald, M. Shaughnessey, FM Crisostomo, and J. Dalessio.

Talk: Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, California (1995). "Development of CMV Vaccines: The Subunit Approach," Rae Lyn Burke, AnneMarie Duliege, Rose Sekulovich, Suresh B. Boppana, William J. Britt, Dan Granoff, and Robert Pass.

Talk: Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, California (1995). "A Recombinant CMV gB Subunit Vaccine with a Novel Adjuvant Can Significantly Boost CMV Antibody Titers in CMV-Seropositive Adults," A. -M. Duliege, S. Frey, S. Boppana, E. Yang, R.L. Burke, R. Sekulovich, S. Hirabayashi, S. Percell, D. Granoff, and R. Pass.

Talk: Thirteenth International Symposium on Laboratory Automation and Robotics, Boston, Massachusetts (1995). "Development and Implementation of Microplate Immunoassays employing Zymark Robotics," J. Patrick McCurley and Rose E. Sekulovich.

Talk: Interscience Conference on Anticmicrobial Agents and Chemotherapy, New Orleans, Louisiana (1996). "Immunotherapy of Recurrent Genital Herpes with Recombinant Glycoprotein Vaccine," S.E. Straus, A. Wald, R. McKenzie, J. Meier, B. Savarese, T. Heineman, J. Ross, A. Langenberg, A. Izu, R. Sekulovich, N. Virani-Ketter, C. Dekker, and L. Corey.

Poster: 16th International Cytomegalovirus Workshop, Orange Beach, Alabama (1997). "Antibody Response to a Fourth Dose of CMV gB Vaccine in Healthy Adults," R. Pass, A.-M. Duliege, R. Sekulovich, S. Boppana, S. Percell, and R.L. Burke.

Poster: 6th International Cytomegalovirus Workshop, Orange Beach, Alabama (1997). "Biocine CMV gB/mf59 Vaccine Induces Antibody Responses When Given at Two Dosages and Three Immunization Schedules," S. Frey, C. Harrison, R. Pass, D. Boken, R. Sekulovich, S. Percell, S. Hirabayashi, and A.-M. Duliege.

Talk: 6th Cytomegalovirus Workshop, Orange Beach, Alabama (1997). "A CMV Glycoprotein gB Subunit Vaccine Elicits Cross Neutralizing Antibodies that Cross Neutralize Clinical Isolates," H. Liu, S. Chou, R. Sekulovich, A.-M. Duliege, and R.L. Burke.

Talk: The American Pediatric Society/The Society for Pediatric Research, (1997). "Immunogenicity of Recombinant Human Cytomegalovirus gB/MF59 Vaccine in Toddlers," D.K. Mitchell, S.J. Holmes, R.L. Burke, R. Sekulovich, M. Tripathi, M. Doyle, and A.-M. Duliege.

Talk: Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (1997). "Safety and Immunogenicity of CMV gB/MF59 Vaccine in Healthy Seronegative Adults," G.S. Marshall, S. Frey, R. Pass, B. Lubin, R. Sekulovich, S. Percell, R.L. Burke, and A.-M. Duliege.

Talk: Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (1997). "Lack of Efficacy of a vaccine containing recombinant gD2 and Gb2 antigens in MF59 adjuvant for the prevention of genital HSV-2 acquisitions," L. Corey, R. Ashley, R. Sekulovich, A. Izu, J. Douglas, H.H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo, A. Adimora, P. Leone, C. Dekker, R.L. Burke, and A. Langenberg.

Poster: American Association of Pharmaceutical Sciences, Salt Lake City, Utah (2003). "Analysis of Herpes Simplex Virus by Reverse Phase HPLC," L. Yu, L. Zhu and R. Sekulovich.

PRESENTATIONS AT SCIENTIFIC MEETINGS

Poster: 10th International Herpesvirus Workshop, University of Michigan, Ann Arbor, Michigan (1985). "ICP0 Affects the Level of HSV-1 Early Proteins during Infection," R.M. Sandri-Goldin, R.E. Sekulovich, and K. Leary.

Poster/Talk: 12th International Herpesvirus Workshop, University of Pennsylvania, Philadelphia, Pennsylvania (1987). "Studies on the Regulatory Activity of ICP27," P.J. Vaughan, R.E. Sekulovich, and R.M. Sandri-Goldin.

Poster: Cold Spring Harbor Vaccines Meeting, Cold Spring Harbor, New York (1989). "A Comparison of the Protective Efficacy of HSV-1 Glycoprotein D presented in Subunit Vaccine versus a Live Virus Vector," R.E. Sekulovich, S-L. Hu, C. Goldbeck, and R.L. Burke.

Talk/Poster: 15th International Herpesvirus Workshop, Georgetown University, Washington, D.C. (1990). "Immunization of Guinea Pigs with a Vaccinia/VP16 Recombinant Virus Elicits Neutralizing Antibody Titers and Protects Against HSV-2 Challenge," R.E. Sekulovich, P. Ng, and R.L. Burke.

Poster: 15th International Herpesvirus Workshop, Georgetown University, Washington, D.C. (1990). "Immunogenicity and Protective Efficacy of HSV-2 Glycoprotein B or D in a Live Virus Vector versus a Subunit Vaccine: Evidence for Superior Efficacy of Subunit Presentation in a Guinea Pig Model," R.E. Sekulovich, I. Ramshaw, P. Ng, and R.L. Burke.

Poster: 18th International Herpesvirus Workshop, Pittsburgh, Pennsylvania (1993). "Analysis of Antibody Isotypes in HSV-2 Glycoprotein Subunit Vaccine Recipients: Effects of Adjuvant and Comparison with Natural Infection," R.E. Sekulovich, S. Klein, D. Higgins, A. Langenberg, and R.L. Burke.

Talk: 6th International Cytomegalovirus Workshop, Orange Beach, Alabama (1997). "Immunogenicity of a Recombinant Human Cytomegalovirus gB/MF59 Vaccine in Toddlers," D.K. Mitchell, S.J. Holmes, A.-M. Duliege, R.L. Burke, R. Sekulovich, M. Tripathi, and M. Doyle.